Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing Watch Now

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price: 1,671.60
Bid: 1,659.20
Ask: 1,660.20
Change: 13.80 (0.83%)
Spread: 1.00 (0.06%)
Open: 1,649.20
High: 1,678.20
Low: 1,646.40
Yest. Close: 1,657.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GlaxoSmithKline seeking marketing approval for 'daprodustat' in Japan

Wed, 21st Aug 2019 08:07

(Sharecast News) - GlaxoSmithKline announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare on Wednesday, seeking marketing approval for 'daprodustat'.
The FTSE 100 pharmaceuticals giant described daprodustat as an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with renal anaemia due to chronic kidney disease (CKD).

It explained that anaemia is common in patients with CKD, as the kidneys no longer produced adequate amounts of erythropoietin - a hormone involved in prompting the production of red blood cells.

HIF-PHIs were a new class of drug, GSK said, that triggered the body's adaptations to hypoxia and encouraged the bone marrow to make more red blood cells, thus benefiting patients with renal anaemia.

The company said the JNDA for daprodustat was primarily based on positive data from the phase 3 programme conducted in Japan.

It said the studies evaluated daprodustat for the treatment of anaemia in patients across the spectrum of CKD, from stages three to five, and included patients on dialysis and those not on dialysis, regardless of prior anaemia treatment with erythropoiesis-stimulating agents.

Daprodustat is not approved as a treatment for renal anaemia or any other indication anywhere in the world at this stage.

If approved, GSK said daprodustat would be exclusively distributed in Japan by Kyowa Kirin, following the strategic commercialisation deal announced by the two companies in 2018.

Launch activities, including the engagement of healthcare professionals and commercial activities, were expected to be conducted jointly by Kyowa Kirin and GSK.

"Around 3.5 million patients in Japan have anaemia associated with renal disease which can result in weakness and fatigue," said GlaxoSmithKline's chief scientific officer and president of research and development, Dr Hal Barron.

"We are excited about our first regulatory filing for daprodustat which, if approved, will provide a new and convenient oral treatment option for these patients."

More News

BROKER RATINGS SUMMARY: Morgan Stanley Raises SSE To Overweight

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:----------FTSE 100----------DEUTSCHE BANK RAISES RENTOKIL INITIAL

10 Sep 19 09:32

Aurora Investment Trust Net Assets Rise But Total Interim Return Lags

(Alliance News) - Aurora Investment Trust PLC on Monday said its net asset value rose in the first six months of the year but total return lagged behind its benchmark index.At June 30, a of

9 Sep 19 12:12

BROKER RATINGS SUMMARY: Deutsche Bank Raises BHP And Cuts Antofagasta

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:----------FTSE 100----------DEUTSCHE BANK RAISES BHP

4 Sep 19 09:32

Tuesday broker round-up

(Sharecast News) - easyJet: Kepler Cheuvreux downgrades to reduce with a target price of 820p.

3 Sep 19 12:59

BROKER RATINGS SUMMARY: Deutsche Bank Starts Taylor Wimpey At Buy

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:----------FTSE 100----------DEUTSCHE BANK INITIATES TAYLOR WIMPEY

3 Sep 19 09:40

LONDON MARKET OPEN: Ferguson-Wolseley Rises; Pound Falls Below USD1.20

(Alliance News) - Stock prices in London opened mixed on Tuesday, with Ferguson the best blue-chip performer after the company decided to split its UK and US operations, while the pound fell below

3 Sep 19 08:49

Monday broker round-up

(Sharecast News) - Beazley: UBS upgrades to buy with a target price of 650p.

2 Sep 19 13:16

Former Glaxo Vice President To Lead C4X Discovery Advisory Network

(Alliance News) - C4X Discovery Holdings PLC on Monday said it is forming a drug discovery advisory network chaired by "renowned industry veteran" Robin Carr.Shares in C4X were up

2 Sep 19 12:02

BROKER RATINGS SUMMARY: Goldman Sachs Says Buy Unilever, Sell M&S

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday afternoon:----------FTSE 100----------GOLDMAN SACHS WITH

2 Sep 19 09:41

BROKER RATINGS SUMMARY: UBS Raises Greggs; Peel Hunt Lifts Chesnara

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday afternoon and Wednesday morning:----------FTSE 100----------KEPLER RAISES

28 Aug 19 09:37

GlaxoSmithKline's Dreamm-2 Multiple Myeloma Trial Results Encouraging

(Alliance News) - GlaxoSmithKline PLC on Friday reported positive headline results from its Dreamm-2 study of belantamab mafodotin in multiple myeloma.The study, which involved 196 patients

23 Aug 19 07:46

GlaxoSmithKline reveals positive results from belantamab mafodotin trial

(Sharecast News) - GlaxoSmithKline announced positive headline results from the pivotal 'DREAMM-2' open-label, randomised study of two doses of belantamab mafodotin on Friday.

23 Aug 19 07:29

Glaxo's ViiV Reports Positive Study Results Of HIV-Treatment Regimen

(Alliance News) - GlaxoSmithKline PLC on Thursday said ViiV Healthcare reported positive headline results from its global phase III ATLAS-2M study.ViiV Healthcare is a specialist HIV owned

22 Aug 19 08:20

GlaxoSmithKline upbeat on latest test results from ViiV Healthcare

(Sharecast News) - GlaxoSmithKline reported on Thursday that its specialist HIV company ViiV Healthcare had announced positive headline results from its phase 3 'ATLAS-2M' study of the investigational, long-acting, injectable, two-drug regimen (2DR) of its cabotegravir and Janssen's rilpivirine for the treatment of HIV.

22 Aug 19 07:29

Glaxo Submits Japanese Application For Daprodustat Anaemia Drug

(Alliance News) - GlaxoSmithKline PLC on Wednesday said it has submitted a new drug application in Japan for anaemia drug daprodustat.The application was submitted to the Japanese Ministry

21 Aug 19 08:38

Login to your account

Don't have an account? Click here to register.